| __timestamp | ImmunityBio, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 10337679 |
| Thursday, January 1, 2015 | 226206000 | 18187286 |
| Friday, January 1, 2016 | 94391000 | 24758063 |
| Sunday, January 1, 2017 | 53821000 | 23666957 |
| Monday, January 1, 2018 | 35463000 | 30099855 |
| Tuesday, January 1, 2019 | 46456000 | 64947625 |
| Wednesday, January 1, 2020 | 71318000 | 186363444 |
| Friday, January 1, 2021 | 135256000 | 272611040 |
| Saturday, January 1, 2022 | 102708000 | 358782000 |
| Sunday, January 1, 2023 | 129620000 | 409864000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and ImmunityBio, Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies, Inc. has seen a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. In contrast, ImmunityBio, Inc. experienced a more volatile trajectory, with a peak in 2015 and fluctuations thereafter. By 2023, Intra-Cellular Therapies, Inc.'s SG&A expenses were approximately 3.2 times higher than those of ImmunityBio, Inc. This trend highlights the aggressive expansion and operational strategies of Intra-Cellular Therapies, Inc., positioning it as a formidable player in the biotech sector. Investors and stakeholders should consider these financial dynamics when evaluating potential growth and investment opportunities.
Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or ImmunityBio, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Catalent, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and MiMedx Group, Inc.